Advanced search
Publication Cover
Clinical Epidemiology Volume 15, 2023 - Issue
Submit an article Journal homepage
226
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Non-Selective Beta-Blockers and Risk of Sepsis in Patients with Cirrhosis and Ascites: Results from a Large Observational Study

Morten Daniel Jensen1 Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, DenmarkCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5137-7268View further author information
ORCID Icon,
Hugh Watson1 Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark;2 Evotec ID (Lyon), Lyon, FranceORCID Iconhttps://orcid.org/0000-0002-6931-3158View further author information
ORCID Icon,
Hendrik Vilstrup1 Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, DenmarkView further author information
&
Peter Jepsen1 Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, DenmarkORCID Iconhttps://orcid.org/0000-0002-6641-1430View further author information
ORCID Icon
Pages 775-783 | Received 06 Dec 2022, Accepted 22 May 2023, Published online: 21 Jun 2023

References

  • Arvaniti V, D’Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139(4):1246. doi:10.1053/j.gastro.2010.06.019
  • Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, et al. Altered intestinal tight junctions’ expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest. 2012;42(4):439–446. doi:10.1111/j.1365-2362.2011.02609.x
  • Xu WH, Wu XJ, Li JS. Influence of portal pressure change on intestinal permeability in patients with portal hypertension. Hepatobiliary Pancreat Dis Int. 2002;1:510–514.
  • Madsen BS, Havelund T, Krag A. Targeting the gut–liver axis in cirrhosis: antibiotics and non-selective β-blockers. Adv Ther. 2013;30:659–670. doi:10.1007/s12325-013-0044-1
  • Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58(5):911–921. doi:10.1016/j.jhep.2012.12.011
  • Merli M, Lucidi C, Di Gregorio V, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2015;35(2):362–369. doi:10.1111/liv.12593
  • Wong F, Watson H, Gerbes A, et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut. 2012;61(1):108–116. doi:10.1136/gutjnl-2011-300157
  • Jepsen P, Watson H, Andersen PK, Vilstrup H. Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients. J Hepatol. 2015;63(5):1133–1138. doi:10.1016/j.jhep.2015.07.007
  • United_Network_for_Organ_Sharing. Changes to OPTN bylaws and policies from actions at OPTN/UNOS executive committee meetings July 2015-November 2015; 2015.
  • Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003;31(4):1250–1256. doi:10.1097/01.CCM.0000050454.01978.3B
  • Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101:1644–1655. doi:10.1378/chest.101.6.1644
  • Bossen L, Krag A, Vilstrup H, Watson H, Jepsen P. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: post Hoc analysis of three randomized controlled trials with 1198 patients. Hepatology. 2016;63(6):1968–1976. doi:10.1002/hep.28352
  • Datta S, Satten GA. Estimation of integrated transition hazards and stage occupation probabilities for non‐Markov systems under dependent censoring. Biometrics. 2002;58:792–802. doi:10.1111/j.0006-341X.2002.00792.x
  • Sanne JW. Willems PDAWvdV. inverse probability censoring weights for routine outcome monitoring data; 2014.
  • Chesnaye NC, Stel VS, Tripepi G, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2021;15:14–20. doi:10.1093/ckj/sfab158
  • Mookerjee RP, Pavesi M, Thomsen KL, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol. 2016;64:574–582. doi:10.1016/j.jhep.2015.10.018
  • Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: evidence-based indications and limitations. JHEP Rep. 2020;2:100063. doi:10.1016/j.jhepr.2019.12.001
  • Sundaram V, Manne V, Al-Osaimi AM. Ascites and spontaneous bacterial peritonitis: recommendations from two United States centers. Saudi J Gastroenterol. 2014;20:279–287. doi:10.4103/1319-3767.141686
  • Sasso R, Rockey DC. Non-selective beta-blocker use in cirrhotic patients is associated with a reduced likelihood of hospitalisation for infection. Aliment Pharmacol Ther. 2021;53:418–425. doi:10.1111/apt.16156
  • Heebøll S, Villadsen GE, Aagaard NK, Grønbæk H, Vilstrup H, Keiding S. Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience. Scand J Gastroenterol. 2013;48:969–973. doi:10.3109/00365521.2013.805811
  • Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393(10181):1597–1608. doi:10.1016/S0140-6736(18)31875-0
  • Villanueva C, Torres F, Sarin SK, et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J Hepatol. 2022;77(4):1014–1025. doi:10.1016/j.jhep.2022.05.021

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.